Biomarkers of epilepsy
https://doi.org/10.25789/YMJ.2019.68.28
Abstract
To date, there are no methods of treatment and prevention of the development of epilepsy in people at risk. All this indicates the need for a search for biomarkers of epileptogenesis, diagnosis, disease progression, drug response and treatment safety.
As biomarkers of epilepsy, the following are considered: electrophysiological changes, the presence of a clinical attack, genetic changes, micro ribonucleic acid (microRNA) of plasma / serum / cerebrospinal fluid; protein biomarkers, plasma exosome biomarkers, cerebral cortex microRNAs; biomarkers, strain gauge images / diffusion-weighted images of magnetic resonance imaging (MRI).
The authors review the literature on modern studies of various biomarkers of epilepsy, which allow a personalized approach to assessing the diagnosis, treatment and response to epilepsy therapy.
Supporting agencies: Source of funding: the research is supported by an intra-University grant for young scientists in accordance with the Grant application No. 2.2, order No. 203 of the OSN from 26.03.2019 of the "Krasnoyarsk state medical University named after Professor V. F. VoynoYasenetsky" Ministry of health of Russia.
About the Authors
K. D. Yakovleva
V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University
Russian Federation
Russian Federation
the resident, laboratory assistant department of medical genetics and clinical neurophysiology
Krasnoyarsk
M. R. Sapronova
V.F. VoinoYasenetsky Krasnoyarsk state medical University
Russian Federation
Russian Federation
Ph. D., associate Professor, department of medical genetics and clinical neurophysiology
A. S. Usoltseva
V.F. VoynoYasenetsky Krasnoyarsk State Medical University
Russian Federation
Russian Federation
the resident, laboratory assistant department of medical genetics and clinical neurophysiology
Krasnoyarsk
Yu. S. Panina
V.F. VoynoYasenetsky Krasnoyarsk State Medical University
Russian Federation
Russian Federation
researcher department of medical genetics and clinical neurophysiology of Institute of postgraduate
Krasnoyarsk
S. N. Zobova
V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University;
Scientific Center of the Siberian Branch of the Russian Academy of Sciences, the Separate Division «Research Institute of Medical Problems of the North»
Russian Federation
Russian Federation
Zobova Svetlana Nikolaevna – Ph. D, research scientist, Department of medical genetics and clinical neurophysiology of Institute of postgraduate education
Krasnoyarsk
D. V. Dmitrenko
V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University
Russian Federation
Russian Federation
MD, head of the department of medical genetics and clinical neurophysiology
Krasnoyarsk
References
1. Biological markers of efficacy and safety of antiepileptic drugs: pharmacogenetics and pharmacokinetics / R.F. Nasyrova, N.A. Sivakova, L.V. Lipatova [et al.] // Siberian medical review. – 2017. – №1 (103). – P. 17-25
2. Genetic characteristics of the metabolism of valproate as a risk factor for adverse drug events / D.V. Dmitrenko, N.A. Shnayder, Y.B. Govorina [et. al.] // Modern problems of science and education. – 2015. – №5. – P.1-9.
3. Dmitrenko D.V. Study of CYP2C9 gene polymorphism in women taking valproates/ D.V. Dmitrenko, N.A. Shnayder // Medical genetics. – 2015. – №10. – P.36-42.
4. Ilae classification of the epilepsies: the 2017 revision and update / G.N. Avakyan, D.V. Blinov, A.V. Lebedeva [et al.] // Epilepsy and paroxysmal conditions. – 2017. – №9(1). -P.6-25. DOI: 10.17749/2077-8333.2017.9.1.006-025.
5. Limbicencephalitis: clinical and laboratory heterogeneity/ N.A. Shnayder, I.A. Kiselev, Yu.S. Panina [et al.] // Yakut medical journal. – 2015. – №1 (49). – P.60-64,
6. Efficacy and safety of valproic acid drugs with delayed release of the active substance in adults in real clinical practice from the perspective of pharmacokinetic and pharmacogenetic approach / P.N. Blasov, N.V. Orekhova, M.V. Antonyuk [et al.] // Neurology, neuropsychiatry, psychosomatics. – 2017. №9. – P.11-20.
7. Advances in the development of biomarkers for epilepsy/ A. Pitkänen, W. Löscher, A. Vezzani [et al.] // Lancet Neurol. – 2016. – №8. – P. 843-856. DOI: 10.1016/S1474-4422(16)00112-5.
8. Altered visual contrast gaincontrol is sensitive for idiopathic generalized epilepsies / D. Won, W. Kim, W.A. Chaovalitwongse [et al.] // Clin. Neurophysiol. – 2017. – №128. – P.340–348. DOI:10.1016/j.clinph.2016.12.008.
9. Aspirin treatment hampers the use of plasma microRNA-126 as abiomarker for the progression of vascular disease / H.C. De Boer, C. van Solingen, J. Prins [et al.] // Eur. Heart J. – 2013. – №34. P.3451–3457. DOI:10.1093/eurheartj/eht007.
10. Atif H. A Review of MicroRNA Biomarkers in Traumatic Brain Injury / Н. Atif, S.D. Hicks // J ExpNeurosci. – 2019. – №13:1179069519832286. DOI: 10.1177/1179069519832286.
11. BEST (Biomarkers, EndpointS, and other Tools) Resource [WWW Document]. — URL: https://www.ncbi.nlm.nih.gov/books/NBK326791/.
12. Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy / J. Wang, L. Tan, L. Tan [et al.] // Sci Rep. – 2015. №5:10201. DOI: 10.1038/srep10201.
13. Cortical gene expression: prognostic value for seizure outcome following temporal lobectomy and amygdalohippocampectomy / M.J. Gallek, J. Skoch, T. Ansay [et al.] // Neurogenetics. – 2016. – №4. –P.211–218. DOI:10.1007/s10048-016-0484-2.
14. Epilepsy biomarkers / l.J. Enge, A. Pitkänen, J.A. Loeb [et al.] // Epilepsia. – 2013. – №54. – P.61-69. DOI: 10.1111/epi.12299.
15. Epilepsy biomarkers – Toward etiology and pathology specificity / A. Pitkänen, X. EkolleNdode-Ekane, N. Lapinlampi [et al.] // Neurobiol Dis. – 2019. – №123: – P. 42-58. DOI: 10.1016/j.nbd.2018.05.007.
16. Epilepsy Research Priorities in Europe.On Behalf of Epilepsy Advocacy Europ e/ E. Perucca, M. Glynn, M. Baulac [et al.] // Epilepsia. – 2015. – №11. – P.1687–1695. DOI:10.1111/epi.13201
17. Frisoni G.B. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers/ G.B. Frisoni, M. Boccardi, F. Barkhof // Lancet Neurol. – 2017. – №8. – P.661-676. DOI: 10.1016/S1474-4422(17)30159-X
18. Genome-wide circulating microRNA expression profiling indicates biomarkers for epilepsy / A.J. Wang, J.T. Yu, L. Tan [et al.] // Sci Rep. – 2015. – №5:9522. DOI: 10.1038/srep09522.
19. Hicks S.D. A Comparative Review of microRNA Expression Patterns in Autism Spectrum Disorder / S.D. Hicks, F.A. Middleton // Front Psychiatry. – 2016. – №4; 7:176. DOI: 10.3389/fpsyt.2016.00176
20. ILAE official report: a practical clinical definition of epilepsy / R.S. Fisher, C. Acevedo, A. Arzimanoglou [et al.] // Epilepsia. – 2014. – №4. – P.475-482. DOI: 10.1111/epi.12550.
21. In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells / A. Rizzo, S. Donzelli, V. Girgenti [et al.] // J ExpClin Cancer Res. – 2017. – №36: 76. DOI:10.1186/s13046-017-0546-9.
22. Kelley M.S. The NINDS epilepsy research benchmarks / M.S. Kelley, M.P. Jacobs, D.H. Lowenstein // Epilepsia. – 2009. – №50. – P.579–582. DOI:10.1111/j.1528-1167.2008.01813.x.
23. MicroRNAs as Diagnostic and Prognostic Biomarkers in Ischemic Stroke-A Comprehensive Review and Bioinformatic Analysis / C. Eyileten, Z. Wicik, S. De Rosa [et al.] // Cells. – 2018. – №6; 7(12). DOI: 10.3390/cells7120249.
24. Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy / L.E. Walker, F. Frigerio, T. Ravizza [et al.] // J Clin Invest. – 2019. – №5:2166. DOI: 10.1172/JCI129285.
25. Personalized translational epilepsy research – Novel approaches and future perspectives: Part I: Clinical and network analysis approaches / S. Bauer, N. van Alphen, A. Becker [et al.] // Epilepsy Behav. – 2017. – №76. P.13-18. DOI: 10.1016/j.yebeh.2017.06.041.
26. Phases of biomarker development for early detection of cancer / M.S. Pepe, R. Etzioni, Z. Feng [et al.] // J Natl Cancer Inst. – 2001. – №14. – P. 1054-1061. DOI: 10.1093/jnci/93.14.1054
27. Reduced local diffusion homogeneity as a biomarker for temporal lobe epilepsy / H.H. Liu, J. Wang, X.M. Chen [et al.] // Medicine (Baltimore). – 2016. – №95.e4032. DOI:10.1097/MD.0000000000004032.
28. Regulation of MicroRNAs-Mediated Autophagic Flux: A New Regulatory Avenue for Neurodegenerative Diseases With Focus on Prion Diseases / S.Z.A. Shah, D. Zhao, T. Hussain [et al.] // Front Aging Neurosci. – 2018. – №10: 139. DOI: 10.3389/fnagi.2018.00139.
29. Traumatic Brain Injury Increases the Expression of Nos1, Aβ Clearance, and Epileptogenesis in APP/PS1 MouseModel of Alzheimer’s Disease / D. Miszczuk, K.J. Dębski, H. Tanila [et al.] // Mol. Neurobiol. – 2016. – №10. – P.7010-7027. DOI:10.1007/s12035-015-9578-3.
30. vanDijkman S.C. Biomarkers in epilepsy – A modelling perspective / S. C. van Dijkman, R. A. Voskuyl, E. C. de Lange // Eur J Pharm Sci. – 2017. – №109. – P.47-52. DOI: 10.1016/j.ejps.2017.05.035.
Review
For citations:
Yakovleva K.D., Sapronova M.R., Usoltseva A.S., Panina Yu.S., Zobova S.N., Dmitrenko D.V. Biomarkers of epilepsy. Yakut Medical Journal. 2019;(4):99-102. https://doi.org/10.25789/YMJ.2019.68.28
Views:
23
Email this article 